Inga-Marie Schaefer1, Meijun Z Lundberg1, Elizabeth G Demicco2,3, Joanna Przybyl4, Magdalena Matusiak4, Frédéric Chibon5, Davis R Ingram6,7, Jason L Hornick1, Wei-Lien Wang6,7, Sebastian Bauer8,9, Laurence H Baker10, Alexander J Lazar6,7, Matt van de Rijn4, Adrian Mariño-Enríquez1, Jonathan A Fletcher1. 1. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, Ontario, Canada. 3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Pathology, Stanford University School of Medicine, Stanford, California. 5. The Institut national de la santé et de la recherche médicale (INSERM) U1037, Cancer Research Center of Toulouse, Department of Pathology, Claudius Régaud Institute, IUCT-Oncopole, Toulouse, France. 6. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen Medical School, Essen, Germany. 9. Partner Site Essen and German Cancer Consortium, Heidelberg, Germany. 10. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Leiomyosarcoma (LMS) is the most common soft tissue and uterine sarcoma, but no standard therapy is available for recurrent or metastatic LMS. TP53, p16/RB1, and PI3K/mTOR pathway dysregulations are recurrent events, and some LMS express estrogen receptor (ER) and/or progesterone receptor (PR). To characterize relationships between these pathway perturbations, the authors evaluated protein expression in soft tissue and uterine nonprimary leiomyosarcoma (np-LMS), including local recurrences and distant metastases. METHODS: TP53, RB1, p16, and PTEN expression aberrations were determined by immunohistochemistry (IHC) in tissue microarrays (TMAs) from 227 np-LMS and a comparison group of 262 primary leiomyosarcomas (p-LMS). Thirty-five of the np-LMS had a matched p-LMS specimen in the TMAs. Correlative studies included differentiation scoring, ER and PR IHC, and CDKN2A/p16 fluorescence in situ hybridization. RESULTS: Dysregulation of TP53, p16/RB1, and PTEN was demonstrated in 90%, 95%, and 41% of np-LMS, respectively. PTEN inactivation was more common in soft tissue np-LMS than uterine np-LMS (55% vs 31%; P = .0005). Moderate-strong ER expression was more common in uterine np-LMS than soft tissue np-LMS (50% vs 7%; P < .0001). Co-inactivation of TP53 and RB1 was found in 81% of np-LMS and was common in both soft tissue and uterine np-LMS (90% and 74%, respectively). RB1, p16, and PTEN aberrations were nearly always conserved in p-LMS and np-LMS from the same patients. CONCLUSIONS: These studies show that nearly all np-LMS have TP53 and/or RB1 aberrations. Therefore, therapies targeting cell cycle and DNA damage checkpoint vulnerabilities should be prioritized for evaluations in LMS.
BACKGROUND: Leiomyosarcoma (LMS) is the most common soft tissue and uterine sarcoma, but no standard therapy is available for recurrent or metastatic LMS. TP53, p16/RB1, and PI3K/mTOR pathway dysregulations are recurrent events, and some LMS express estrogen receptor (ER) and/or progesterone receptor (PR). To characterize relationships between these pathway perturbations, the authors evaluated protein expression in soft tissue and uterine nonprimary leiomyosarcoma (np-LMS), including local recurrences and distant metastases. METHODS: TP53, RB1, p16, and PTEN expression aberrations were determined by immunohistochemistry (IHC) in tissue microarrays (TMAs) from 227 np-LMS and a comparison group of 262 primary leiomyosarcomas (p-LMS). Thirty-five of the np-LMS had a matched p-LMS specimen in the TMAs. Correlative studies included differentiation scoring, ER and PR IHC, and CDKN2A/p16 fluorescence in situ hybridization. RESULTS: Dysregulation of TP53, p16/RB1, and PTEN was demonstrated in 90%, 95%, and 41% of np-LMS, respectively. PTEN inactivation was more common in soft tissue np-LMS than uterine np-LMS (55% vs 31%; P = .0005). Moderate-strong ER expression was more common in uterine np-LMS than soft tissue np-LMS (50% vs 7%; P < .0001). Co-inactivation of TP53 and RB1 was found in 81% of np-LMS and was common in both soft tissue and uterine np-LMS (90% and 74%, respectively). RB1, p16, and PTEN aberrations were nearly always conserved in p-LMS and np-LMS from the same patients. CONCLUSIONS: These studies show that nearly all np-LMS have TP53 and/or RB1 aberrations. Therefore, therapies targeting cell cycle and DNA damage checkpoint vulnerabilities should be prioritized for evaluations in LMS.
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Julia A Elvin; Laurie M Gay; Rita Ort; Joseph Shuluk; Jennifer Long; Lauren Shelley; Ronald Lee; Zachary R Chalmers; Garrett M Frampton; Siraj M Ali; Alexa B Schrock; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Richard Frank Journal: Oncologist Date: 2017-03-10
Authors: Inigo Espinosa; Andrew H Beck; Cheng-Han Lee; Shirley Zhu; Kelli D Montgomery; Robert J Marinelli; Kristen N Ganjoo; Torsten O Nielsen; C Blake Gilks; Robert B West; Matt van de Rijn Journal: Am J Pathol Date: 2009-05-14 Impact factor: 4.307
Authors: A M Goldstein; M C Fraser; J P Struewing; C J Hussussian; K Ranade; D P Zametkin; L S Fontaine; S M Organic; N C Dracopoli; W H Clark Journal: N Engl J Med Date: 1995-10-12 Impact factor: 91.245
Authors: Michael J Böhm; Ralf Marienfeld; Daniela Jäger; Kevin Mellert; Adrian von Witzleben; Silke Brüderlein; Mathias Wittau; Alexandra von Baer; Markus Schultheiss; Regine Mayer-Steinacker; Frank G Rücker; Peter Möller; Lars Bullinger; Thomas F E Barth Journal: Sarcoma Date: 2019-01-21
Authors: Inga-Marie Schaefer; Matthew L Hemming; Meijun Z Lundberg; Matthew P Serrata; Isabel Goldaracena; Ninning Liu; Peng Yin; Joao A Paulo; Steven P Gygi; Suzanne George; Jeffrey A Morgan; Monica M Bertagnolli; Ewa T Sicinska; Chen Chu; Shanshan Zheng; Adrian Mariño-Enríquez; Jason L Hornick; Chandrajit P Raut; Wen-Bin Ou; George D Demetri; Sinem K Saka; Jonathan A Fletcher Journal: Br J Cancer Date: 2022-09-29 Impact factor: 9.075
Authors: Matthew L Hemming; Patrick Bhola; Michael A Loycano; Justin A Anderson; Madeleine L Taddei; Leona A Doyle; Elizaveta Lavrova; Jessica L Andersen; Kelly S Klega; Morgan R Benson; Brian D Crompton; Chandrajit P Raut; Suzanne George; Anthony Letai; George D Demetri; Ewa Sicinska Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801